Pluriomics, a Leiden, The Netherlands, and Gosselies, Belgium-based biotechnology company expert in human cardiovascular stem cell technology, raised €2.5m in funding.
Backers included SFPI-FPIM (The Federal Holding and Investment Company) and SambrInvest.
The funds will be used to speed up its international growth, to develop cardiac safety assays and to expand capabilities in the cardiovascular drug discovery and high throughput screening domain.
Led by Stefan Braam, CEO, Pluriomics aims to deliver cardiac drug discovery and safety solutions based on its human iPSC-derived cardiomyocyte technology.
The company manufactures human induced pluripotent stem cell derived cardiomyocytes (Pluricyte® Cardiomyocytes) using serum-free medium that enhances the maturation and function of the cells.